Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Dynavax Technologies Corp (DVAX) Common Stock USD0.001

Sell:$4.10 Buy:$4.22 Change: $0.04 (0.95%)
NASDAQ:0.37%
Market closed |  Prices as at close on 23 October 2020 | Switch to live prices |
Sell:$4.10
Buy:$4.22
Change: $0.04 (0.95%)
Market closed |  Prices as at close on 23 October 2020 | Switch to live prices |
Sell:$4.10
Buy:$4.22
Change: $0.04 (0.95%)
Market closed |  Prices as at close on 23 October 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.

Contact details

Address:
2100 POWELL STREET, SUITE 900
EMERYVILLE
94608
United States
Telephone:
+1 (510) 8485100
Website:
www.dynavax.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
DVAX
ISIN:
US2681582019
Market cap:
$456.66 million
Shares in issue:
109.51 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Andrew Hack
    Interim Independent Chairman of the Board
  • David Novack
    President, Chief Operating Officer
  • Ryan Spencer
    Chief Executive Officer, Director
  • Michael Ostrach
    Senior Vice President, Chief Financial Officer and Chief Business Officer
  • Steven Gersten
    Senior Vice President, General Counsel, Chief Ethics and Compliance Officer and Secretary
  • Jeff Coon
    Senior Vice President of Human Resources and Corporate Services
  • Robert Janssen
    Chief Medical Officer and Senior Vice President, Clinical Development
  • Justin Burgess
    Principal Accounting Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.